- Home >
- Publications >
- Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
Authors
Mariana Brandão, Fabien Reyal, Anne-Sophie Hamy, Martine Piccart-Gebhart